A Joint Venture for New Treatment of Rare Pediatric Epilepsies!
Pharmaceutical companies Takeda and Ovid have agreed to work together to develop a new drug for rare pediatric epilepsies. The continued development of Takeda’s compound TAK-935 will be shared by…